Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System
Open Access
- 27 March 2017
- journal article
- review article
- Published by Springer Nature in Current HIV/AIDS Reports
- Vol. 14 (2) , 54-62
Abstract
The purpose of this study is to summarize recent advances in the use of broadly neutralizing antibodies (bNAbs) as therapeutics in human clinical trials and in non-human primate (NHP) models. We seek to highlight lessons from these studies with an emphasis on consequences to the virus and immune system.Keywords
This publication has 56 references indexed in Scilit:
- Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T CellsPLOS Pathogens, 2015
- AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challengesNature, 2015
- Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and ImmunotypesPLOS Pathogens, 2013
- Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeysNature, 2013
- Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escapeNature Medicine, 2012
- The Antibody Response against HIV-1Cold Spring Harbor Perspectives in Medicine, 2011
- Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 LoopJournal of Virology, 2011
- Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C InfectionPLOS Pathogens, 2009
- In Vivo and In Vitro Escape from Neutralizing Antibodies 2G12, 2F5, and 4E10Journal of Virology, 2007
- A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1AIDS, 2002